Semaphorin 4C (SEMA4C) and its corresponding receptor, PlexinB2, are overexpressed in breast cancer tissue, with implications for both cancer progression and metastasis, as well as resistance to hormonal and chemotherapy. Here, SEMA4C is linked to breast cancer.